Morgan Stanley Reveals Its Top 5 Stock Selections for 2026

Key Highlights

Table of Contents

Affirm (AFRM) identified as underpriced with upcoming investor forum set for May 12 serving as potential stock catalyst
UnitedHealth (UNH) elevated to top recommendation following strong Q1 2026 performance and upgraded annual projections
Meta (META) positioned as Morgan Stanley’s leading big tech selection prior to Q1 2026 earnings release on April 29
CrowdStrike (CRWD) designated premier software investment after surpassing $5 billion ARR milestone with expanding growth rates
Seagate (STX) chosen over Western Digital due to superior margin growth prospects and AI-driven storage opportunities

Morgan Stanley has unveiled five equities as its premier investment selections for 2026. While spanning diverse market sectors, these picks share common characteristics: demonstrable earnings momentum, imminent catalysts, and appreciation potential the investment bank believes remains underrecognized by the broader market.

Affirm (AFRM)

Equity analyst James Faucette characterized Affirm as trading below intrinsic value. He contends that investor anxiety surrounding the firm’s private credit involvement appears excessive. The fundamental investment thesis centers on the company’s buy now, pay later business framework.

Affirm Holdings, Inc., AFRM

An investor forum scheduled for May 12 represents a potentially pivotal event, offering management an opportunity to elevate medium-range financial targets. Additionally, Affirm will release its fiscal third-quarter 2026 financial results on May 7.

UnitedHealth Group (UNH)

Morgan Stanley elevated UnitedHealth to top pick status on April 16. This upgrade followed the implementation of more advantageous Medicare Advantage reimbursement rates benefiting the healthcare giant.

UnitedHealth Group Incorporated, UNH

UnitedHealth delivered first-quarter 2026 adjusted earnings of $7.23 per share on revenues totaling $111.7 billion, exceeding analyst projections on both metrics. Management subsequently increased full-year earnings guidance to surpass $18.25 per share.

Meta Platforms (META)

Morgan Stanley designated Meta as its top choice among large-cap technology companies entering earnings season. The investment firm anticipates a more robust earnings expansion trajectory compared to sector peers, powered by artificial intelligence enhancements to advertising effectiveness throughout its platform ecosystem.

Meta is scheduled to announce Q1 2026 financial results on April 29. The company’s 2025 annual revenue climbed 22%, with executives projecting 2026 operating income will surpass 2025 performance despite substantial infrastructure capital expenditures.

CrowdStrike (CRWD)

Morgan Stanley elevated CrowdStrike to an Overweight rating in March while simultaneously naming it the premier selection within the software sector. The firm characterizes it as among the best-positioned cybersecurity enterprises to continue capturing market share.

This assessment stems from the Falcon Flex platform’s capabilities and dominance in endpoint protection. CrowdStrike exceeded $5 billion in ending annual recurring revenue, achieved 24% ARR growth, and delivered its inaugural full year of positive GAAP net income accompanied by record free cash flow generation.

Seagate Technology (STX)

Morgan Stanley currently favors Seagate over Western Digital within the hard disk drive industry. The rationale emphasizes superior gross margin expansion capabilities and stronger competitive positioning in high-capacity storage solutions.

The investment thesis holds that traditional hard drives represent an underappreciated beneficiary of AI-generated data proliferation and escalating cloud storage requirements. Morgan Stanley considers Seagate’s forthcoming earnings announcement as a critical evaluation of pricing strength and supply constraints.

Seagate will report fiscal third-quarter 2026 results on April 28. This earnings release represents the most proximate data point among Morgan Stanley’s recommendations and serves as the earliest validation opportunity for the firm’s investment thesis.